SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan D. Green on March 5, 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is gaining significant community attention as investors debate its potential as a strategic acquisition target amidst high short interest and aggressive share repurchases. Discussion is centered on its valuation relative to competitors, its operational shift toward an asset-light model through partnerships, and the anticipation surrounding upcoming earnings as a key indicator of margin and bookings growth.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals is experiencing active community discussion following the recent announcement of a definitive agreement to acquire Crinetics Pharmaceuticals for $10 billion, a move investors see as a major strategic effort to expand its rare disease pipeline beyond cystic fibrosis. Traders are closely monitoring the deal's potential to provide long-term growth through Crinetics' lead endocrine assets, while some market participants remain focused on Vertex's broader pipeline and its ability to maintain high operating margins.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class A

Berkshire Hathaway is trending as investors digest Warren Buffett's transition away from daily operations and the company's record-breaking cash pile, which has sparked intense debate over potential large-scale acquisitions and future capital allocation strategies. The community remains focused on CEO Greg Abels ability to deploy these assets effectively while maintaining the firm's long-term discipline amid a shifting macroeconomic landscape.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently trending due to a combination of social media speculation regarding a potential price squeeze and a surge in community engagement surrounding its long-term technological potential. While some traders are focused on technical support levels and recent listing news, others are actively debating the token's future in the context of institutional adoption and the broader crypto market landscape.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

Churchill Capital Corp XI is trending as investors focus on its pending merger with Agility Robotics, a company positioned as a pure-play leader in humanoid robotics with strong strategic backing from industry giants like Amazon and NVIDIA. The community is actively discussing the stock's potential for massive long-term growth and its unique position in the physical AI sector, while monitoring institutional positioning from major hedge funds.

General Mills, Inc. engages in the manufacture of food. Its portfolio of brands includes household names like Cheerios, Nature Valley, Blue Buffalo, Häagen-Dazs, Old El Paso, Pillsbury, Betty Crocker, Totino’s, Annie’s, Wanchai Ferry and more. It operates through the following segments: North America Retail, International, North America Pet, and North America Foodservice. The North America Retail segment includes grocery stores, mass merchandisers, membership stores, natural food chains, drug, dollar and discount chains, convenience stores, and e-commerce grocery providers. The International segment refers to the retail and foodservice businesses outside of the US and Canada. The North America Pet segment includes pet food products sold in national pet superstore chains, e-commerce retailers, grocery stores, regional pet store chains, mass merchandisers, and veterinary clinics and hospitals. The North America Foodservice segment offers ready-to-eat cereals, snacks, refrigerated yogurt, frozen meals, unbaked and fully baked frozen dough products, baking mixes, and bakery flour. The company was founded by Cadwallader C. Washburn on June 20, 1928 and is headquartered in Minneapolis, MN.

General Mills, Inc.

General Mills is trending as investors debate whether the recent slump reflects a fundamental decline in consumer staples or an oversold opportunity for long-term income, fueled by aggressive analyst downgrades and widespread debate over the impact of GLP-1 drugs on snacking habits. The community is actively discussing the stock's stability, its attractive dividend yield, and its status as a defensive play against tech-heavy volatility ahead of upcoming earnings.

Ethena

Ethena is capturing significant attention as investors react to institutional backing, potential integration into major stablecoin platforms, and aggressive treasury buyback strategies. The community is actively debating the token's long-term viability amid volatility, focusing on key technical breakouts and its role in the broader shift toward synthetic dollar adoption.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is currently facing intense community debate as investors weigh concerns over continued price depreciation against the potential for a technical turnaround driven by the Polkadot 2.0 upgrade and new supply cap initiatives. While skeptics highlight the token's prolonged downtrend and lack of immediate institutional demand, bulls continue to emphasize its core architecture, high developer activity, and anticipation of broader regulatory clarity as catalysts for long-term recovery.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devon Energy is trending due to the anticipation of its upcoming earnings report and significant community buzz surrounding the strategic $58 billion merger with Coterra Energy, which aims to optimize Permian Basin operations and drive substantial operational synergies. Investors are actively debating the potential for increased shareholder returns through buybacks and dividends, while monitoring heightened geopolitical tensions in the Middle East that keep global energy supply concerns in the spotlight.

Themes ETF Trust - Leverage Shares 2X Long SPCX Daily ETF

Leverage Shares 2x Long SPCX Daily ETF

The SPCH 2x Long SpaceX Daily ETF is seeing intense volatility and high trading volume as investors aggressively scalp the stock alongside its underlying asset. Traders are actively debating the impact of upcoming lockup expirations and SpaceX's recent public market activity, often utilizing the leveraged fund for short-term momentum plays despite warnings about the risks of holding these vehicles overnight.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE

Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group...

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit...

SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit

SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud...

Class Action Filed Against Skye Bioscience, Inc. (SKYE) - January 16, 2026 Deadline to Join - Contact The Gross Law Firm

Class Action Filed Against Skye Bioscience, Inc. (SKYE) - January 16, 2026 Deadline to Join - Contact The Gross Law Firm Class Action Filed Against Skye Bioscience, Inc. (SKYE) - January 16, 2026...

SKYE Deadline: Rosen Law Firm Urges Skye Bioscience, Inc. (NASDAQ: SKYE) Stockholders to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025. Skye is a clinical stage...

Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before January 16, 2026 to Discuss Your Rights - SKYE

Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before January 16, 2026 to Discuss Your Rights - SKYE Skye Bioscience, Inc. Securities Fraud Class...

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK...

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 6, 2026 NEW YORK...

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience...

$SKYE Q1 '26 Earnings Results & Recap

Reported GAAP EPS of -$0.32 down -14.29% YoY

Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.

Skye Bioscience Inc

Why Did Skye Bioscience Stock Plummet A Whopping 60% Today?

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.5685
Prev Close	$0.5803
Open	$0.57
Dividend Yield	0.00%
50-Day Moving Average	$0.7048
Beta	0.99
Avg. Volume	171,125.40
PE Ratio	-0.39

52-Week High	$4.99
52-Week Low	$0.56
Market Capitalization	$19.98M
EPS (Annual)	-$1.41
Price to Book	2.22
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info